View ValuationMaxigen Biotech 将来の成長Future 基準チェック /06現在、 Maxigen Biotechの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長30.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesReported Earnings • May 01First quarter 2026 earnings released: EPS: NT$0.59 (vs NT$0.53 in 1Q 2025)First quarter 2026 results: EPS: NT$0.59 (up from NT$0.53 in 1Q 2025). Revenue: NT$190.9m (up 7.7% from 1Q 2025). Net income: NT$52.8m (up 12% from 1Q 2025). Profit margin: 28% (up from 27% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$2.96 (vs NT$2.13 in FY 2024)Full year 2025 results: EPS: NT$2.96 (up from NT$2.13 in FY 2024). Revenue: NT$811.6m (up 19% from FY 2024). Net income: NT$265.3m (up 40% from FY 2024). Profit margin: 33% (up from 28% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • Mar 12Maxigen Biotech Inc., Annual General Meeting, Jun 11, 2026Maxigen Biotech Inc., Annual General Meeting, Jun 11, 2026. Location: 3 floor no,88, k`o chi 1st rd., gueishan district, taoyuan city TaiwanReported Earnings • Nov 12Third quarter 2025 earnings released: EPS: NT$0.84 (vs NT$0.56 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.84 (up from NT$0.56 in 3Q 2024). Revenue: NT$200.9m (up 16% from 3Q 2024). Net income: NT$75.5m (up 53% from 3Q 2024). Profit margin: 38% (up from 28% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Aug 29Upcoming dividend of NT$0.83 per shareEligible shareholders must have bought the stock before 05 September 2025. Payment date: 30 September 2025. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (1.1%).Reported Earnings • Aug 13Second quarter 2025 earnings released: EPS: NT$0.66 (vs NT$0.67 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.66 (down from NT$0.67 in 2Q 2024). Revenue: NT$208.8m (up 20% from 2Q 2024). Net income: NT$58.9m (down 1.3% from 2Q 2024). Profit margin: 28% (down from 34% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.お知らせ • Jun 12Maxigen Biotech Inc. Appoints Shih-An Chen as Independent Director, Effective June 11, 2025Maxigen Biotech Inc. announced the appointment of Shih-An Chen as Independent Director. Shih-An Chen is an Honorary Director of Taichung Veterans General Hospital. The change is due to a by-election, and the effective date of the new appointment is June 11, 2025. Original term from June 13, 2024 to June 12, 2027.Reported Earnings • May 01First quarter 2025 earnings released: EPS: NT$0.53 (vs NT$0.32 in 1Q 2024)First quarter 2025 results: EPS: NT$0.53 (up from NT$0.32 in 1Q 2024). Revenue: NT$177.2m (up 39% from 1Q 2024). Net income: NT$47.1m (up 66% from 1Q 2024). Profit margin: 27% (up from 22% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 22Maxigen Biotech Inc. to Report Q1, 2025 Results on Apr 29, 2025Maxigen Biotech Inc. announced that they will report Q1, 2025 results on Apr 29, 2025New Risk • Apr 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.22b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$36.15, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 28x in the Biotechs industry in Taiwan. Total returns to shareholders of 2.0% over the past three years.Reported Earnings • Mar 05Full year 2024 earnings released: EPS: NT$2.13 (vs NT$1.87 in FY 2023)Full year 2024 results: EPS: NT$2.13 (up from NT$1.87 in FY 2023). Revenue: NT$680.7m (up 9.4% from FY 2023). Net income: NT$190.2m (up 15% from FY 2023). Profit margin: 28% (up from 27% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.お知らせ • Feb 27Maxigen Biotech Inc., Annual General Meeting, Jun 11, 2025Maxigen Biotech Inc., Annual General Meeting, Jun 11, 2025. Location: 3 floor no,88, k`o chi 1st rd., gueishan district, taoyuan city Taiwanお知らせ • Feb 19Maxigen Biotech Inc. to Report Fiscal Year 2024 Results on Feb 26, 2025Maxigen Biotech Inc. announced that they will report fiscal year 2024 results on Feb 26, 2025分析記事 • Nov 20Maxigen Biotech's (TWSE:1783) Shareholders Have More To Worry About Than Only Soft EarningsMaxigen Biotech Inc.'s ( TWSE:1783 ) recent weak earnings report didn't cause a big stock movement. We think that...Reported Earnings • Nov 18Third quarter 2024 earnings released: EPS: NT$0.56 (vs NT$0.47 in 3Q 2023)Third quarter 2024 results: EPS: NT$0.56 (up from NT$0.47 in 3Q 2023). Revenue: NT$173.9m (up 9.1% from 3Q 2023). Net income: NT$49.5m (up 20% from 3Q 2023). Profit margin: 28% (up from 26% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: NT$0.66 (vs NT$0.70 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.66 (down from NT$0.70 in 2Q 2023). Revenue: NT$174.0m (up 1.8% from 2Q 2023). Net income: NT$59.7m (down 4.2% from 2Q 2023). Profit margin: 34% (down from 37% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.お知らせ • Jul 20Maxigen Biotech Inc. to Report Q2, 2024 Results on Jul 29, 2024Maxigen Biotech Inc. announced that they will report Q2, 2024 results on Jul 29, 2024Upcoming Dividend • Jul 16Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 23 July 2024. Payment date: 16 August 2024. Payout ratio is a comfortable 59% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of Taiwanese dividend payers (4.2%). Lower than average of industry peers (2.5%).New Risk • May 24New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.Reported Earnings • May 07First quarter 2024 earnings released: EPS: NT$0.32 (vs NT$0.50 in 1Q 2023)First quarter 2024 results: EPS: NT$0.32 (down from NT$0.50 in 1Q 2023). Revenue: NT$127.1m (down 11% from 1Q 2023). Net income: NT$28.4m (down 36% from 1Q 2023). Profit margin: 22% (down from 31% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 28Maxigen Biotech Inc. to Report Q1, 2024 Results on May 03, 2024Maxigen Biotech Inc. announced that they will report Q1, 2024 results at 9:00 AM, Taipei Standard Time on May 03, 2024分析記事 • Mar 28Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable QualityDespite posting some strong earnings, the market for Maxigen Biotech Inc.'s ( TWSE:1783 ) stock hasn't moved much. We...Reported Earnings • Mar 24Full year 2023 earnings released: EPS: NT$1.86 (vs NT$1.57 in FY 2022)Full year 2023 results: EPS: NT$1.86 (up from NT$1.57 in FY 2022). Revenue: NT$622.1m (up 2.9% from FY 2022). Net income: NT$165.8m (up 19% from FY 2022). Profit margin: 27% (up from 23% in FY 2022). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 14Maxigen Biotech Inc., Annual General Meeting, Jun 13, 2024Maxigen Biotech Inc., Annual General Meeting, Jun 13, 2024. Location: location:No. 88, Keji 1st Rd., Guishan District Taoyuan City 3rd Floor Meeting Room of the Company Taoyuan Taiwan Agenda: To consider the Company's 2023 Business Report; to audit Committee's review of the 2023 annual final accounting books and statements; to consider 2023 Annual Report on remuneration of Individual Directors; and to discuss other matters.Buying Opportunity • Oct 12Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be NT$64.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 36%.Upcoming Dividend • Aug 31Upcoming dividend of NT$0.50 per share at 0.9% yieldEligible shareholders must have bought the stock before 07 September 2023. Payment date: 12 October 2023. Trailing yield: 0.9%. Lower than top quartile of Taiwanese dividend payers (5.6%). Lower than average of industry peers (3.0%).お知らせ • Aug 24Maxigen Biotech Inc. Declares Dividend, Payable on October 12, 2023Maxigen Biotech Inc. announced cash dividends of TWD 42,349,579 with TWD 0.5 distribution per share. Ex-rights (ex-dividend) trading date is September 7, 2023. Ex-rights (ex-dividend) record date is September 13, 2023. Payment date of cash dividend distribution is October 12, 2023.Buying Opportunity • Aug 23Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 8.9%. The fair value is estimated to be NT$68.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 36%.Reported Earnings • Jul 27Second quarter 2023 earnings released: EPS: NT$0.74 (vs NT$0.40 in 2Q 2022)Second quarter 2023 results: EPS: NT$0.74 (up from NT$0.40 in 2Q 2022). Revenue: NT$170.9m (up 11% from 2Q 2022). Net income: NT$62.3m (up 86% from 2Q 2022). Profit margin: 37% (up from 22% in 2Q 2022). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year whereas the company’s share price has increased by 40% per year.Buying Opportunity • Jun 28Now 21% undervaluedOver the last 90 days, the stock is up 12%. The fair value is estimated to be NT$78.69, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 29%.お知らせ • May 05Maxigen Biotech Inc. Announces Cash Dividend for the Period from January 1, 2022 to December 31, 2022Maxigen Biotech Inc. announced cash dividend of TWD 0.5 per share to the shareholders for the period from January 1, 2022 to December 31, 2022.Valuation Update With 7 Day Price Move • May 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$69.30, the stock trades at a trailing P/E ratio of 42.1x. Average trailing P/E is 34x in the Personal Products industry in Taiwan. Total returns to shareholders of 189% over the past three years.Reported Earnings • Mar 26Full year 2022 earnings released: EPS: NT$1.65 (vs NT$1.10 in FY 2021)Full year 2022 results: EPS: NT$1.65 (up from NT$1.10 in FY 2021). Revenue: NT$604.4m (up 18% from FY 2021). Net income: NT$139.4m (up 59% from FY 2021). Profit margin: 23% (up from 17% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$57.80, the stock trades at a trailing P/E ratio of 44.5x. Average trailing P/E is 30x in the Personal Products industry in Taiwan. Total returns to shareholders of 183% over the past three years.お知らせ • Dec 30Maxigen Biotech Inc. Announces Resignation of You Wan-How as Financial Officer and Accounting OfficerMaxigen Biotech Inc. Announces Resignation of You Wan-How as Financial Officer and Accounting Officer. Type of personnel changed: financial officer and accounting officer. Date of occurrence of the change:2022/12/29. Name, title, and resume of the previous position holder: You Wan-How/financial officer and accounting officer of MBI. Name, title, and resume of the new position holder: None. Type of the change: Resignation. Effective date:2022/12/29. The new financial and accounting officer will be announced after audit committee and the board of directors approve the appointment.Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 3 independent directors (4 non-independent directors). Representative Director Tsiu-Yuan Li is the most experienced director on the board, commencing their role in 2015. Independent Director Sung-Yuan Liao was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 26Third quarter 2022 earnings released: EPS: NT$0.55 (vs NT$0.42 in 3Q 2021)Third quarter 2022 results: EPS: NT$0.55 (up from NT$0.42 in 3Q 2021). Revenue: NT$162.6m (up 17% from 3Q 2021). Net income: NT$42.1m (up 36% from 3Q 2021). Profit margin: 26% (up from 22% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 06Second quarter 2022 earnings released: EPS: NT$0.43 (vs NT$0.31 in 2Q 2021)Second quarter 2022 results: EPS: NT$0.43 (up from NT$0.31 in 2Q 2021). Revenue: NT$154.2m (up 27% from 2Q 2021). Net income: NT$33.5m (up 56% from 2Q 2021). Profit margin: 22% (up from 18% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 19% per year.Valuation Update With 7 Day Price Move • Jun 30Investor sentiment improved over the past weekAfter last week's 17% share price gain to NT$48.00, the stock trades at a trailing P/E ratio of 42.7x. Average trailing P/E is 18x in the Personal Products industry in Taiwan. Total returns to shareholders of 96% over the past three years.お知らせ • May 14Maxigen Biotech Inc. Announces Resignation of Lu Min Hsuan as Chief Internal AuditorMaxigen Biotech Inc. announced the resignation of Lu Min Hsuan as chief internal auditor of the company, with effect from May 13, 2022. The new chief internal auditor will be announced after audit committee and the board of directors approve the appointment.Reported Earnings • May 04First quarter 2022 earnings released: EPS: NT$0.27 (vs NT$0.31 in 1Q 2021)First quarter 2022 results: EPS: NT$0.27 (down from NT$0.31 in 1Q 2021). Revenue: NT$123.3m (up 11% from 1Q 2021). Net income: NT$20.5m (down 5.0% from 1Q 2021). Profit margin: 17% (down from 20% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 15% per year.お知らせ • May 04+ 1 more updateMaxigen Biotech Inc. Appoints Lin Yung-Hsiang to Nomination CommitteeMaxigen Biotech Inc. announced the appointment of Lin Yung-Hsiang to the Company's Nomination Committee, with effect from May 3, 2022.Valuation Update With 7 Day Price Move • Apr 29Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to NT$37.65, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 56% over the past three years.Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Zhong Ming Zeng is the most experienced director on the board, commencing their role in 2021. Independent Director Song-Yuan Liao was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Mar 23Maxigen Biotech Inc., Annual General Meeting, Jun 21, 2022Maxigen Biotech Inc., Annual General Meeting, Jun 21, 2022. Location: No. 88, Keji 1st Rd., Guishan District (3rd Floor Meeting Room of the Company) Taoyuan City Taiwan Agenda: To consider the Company's 2021 Business Report; to consider audit committee's review of the 2021 annual final accounting books and statements; to consider report on 2021 employees and Directors' remuneration; to consider 2021 Annual Report on remuneration of Individual Directors; to consider 2021 Business Report and Financial Statements; to consider proposal of 2021 earnings distribution; to consider issue new shares through the capitalization of retained earnings; to approve the lifting of non competition restrictions for directors and representatives; and to consider and discuss other matters (if any).Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.18 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$138.6m (up 20% from 3Q 2020). Net income: NT$30.9m (up 153% from 3Q 2020). Profit margin: 22% (up from 11% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Oct 04Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to NT$51.80, the stock trades at a trailing P/E ratio of 52.8x. Average trailing P/E is 14x in the Personal Products industry in Taiwan. Total returns to shareholders of 99% over the past three years.Reported Earnings • Aug 12Second quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.30 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: NT$121.1m (up 4.0% from 2Q 2020). Net income: NT$21.4m (up 4.2% from 2Q 2020). Profit margin: 18% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Aug 12Upcoming dividend of NT$0.73 per shareEligible shareholders must have bought the stock before 19 August 2021. Payment date: 13 September 2021. Trailing yield: 1.1%. Lower than top quartile of Taiwanese dividend payers (5.1%). Lower than average of industry peers (3.7%).Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improved over the past weekAfter last week's 24% share price gain to NT$49.65, the stock trades at a trailing P/E ratio of 46.1x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total returns to shareholders of 72% over the past three years.Reported Earnings • May 16First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.15 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: NT$111.0m (up 7.4% from 1Q 2020). Net income: NT$21.6m (up 112% from 1Q 2020). Profit margin: 20% (up from 9.9% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.分析記事 • Apr 22Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?Could Maxigen Biotech Inc. ( TPE:1783 ) be an attractive dividend share to own for the long haul? Investors are often...分析記事 • Apr 01We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) EarningsThe market shrugged off Maxigen Biotech Inc.'s ( TPE:1783 ) solid earnings report. We think that investors might be...Reported Earnings • Mar 23Full year 2020 earnings released: EPS NT$0.91 (vs NT$0.86 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: NT$457.7m (up 1.2% from FY 2019). Net income: NT$63.3m (up 5.3% from FY 2019). Profit margin: 14% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.分析記事 • Mar 16Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?Maxigen Biotech's (TPE:1783) stock is up by a considerable 26% over the past three months. Given that stock prices are...Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$27.50, the stock is trading at a trailing P/E ratio of 37.9x, up from the previous P/E ratio of 32.3x. This compares to an average P/E of 17x in the Personal Products industry in Taiwan. Total returns to shareholders over the past three years are 36%.分析記事 • Feb 23The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For MoreBuying a low-cost index fund will get you the average market return. But if you invest in individual stocks, some are...Is New 90 Day High Low • Feb 20New 90-day high: NT$24.00The company is up 2.0% from its price of NT$23.50 on 20 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 6.0% over the same period.分析記事 • Feb 02Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...分析記事 • Jan 10Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend YieldToday we'll take a closer look at Maxigen Biotech Inc. ( TPE:1783 ) from a dividend investor's perspective. Owning a...分析記事 • Dec 14Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?Maxigen Biotech (TPE:1783) has had a rough three months with its share price down 7.2%. However, the company's...分析記事 • Nov 22If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results...Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS NT$0.18The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$115.1m (down 4.6% from 3Q 2019). Net income: NT$12.2m (down 37% from 3Q 2019). Profit margin: 11% (down from 16% in 3Q 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 30New 90-day low: NT$22.15The company is down 19% from its price of NT$27.25 on 31 July 2020. The Taiwanese market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 9.0% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: NT$23.05The company is down 21% from its price of NT$29.35 on 24 June 2020. The Taiwanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Maxigen Biotech は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TWSE:1783 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026825271210295N/A12/31/2025812265208290N/A9/30/2025792234223277N/A6/30/2025766208273310N/A3/31/2025731209287319N/A12/31/2024681190266298N/A9/30/2024624155246272N/A6/30/2024609147149173N/A3/31/2024606150178201N/A12/31/2023622166149171N/A9/30/2023638191174192N/A6/30/2023641192232249N/A3/31/2023624163219235N/A12/31/2022604139254268N/A9/30/2022581110222236N/A6/30/202255799183203N/A3/31/202252487132153N/A12/31/202151288102118N/A9/30/202149494124139N/A6/30/202147076117124N/A3/31/20214657593100N/A12/31/2020458636375N/A9/30/2020447502859N/A6/30/2020452584769N/A3/31/2020463645175N/A12/31/201945260N/A94N/A9/30/201943460N/A77N/A6/30/201942758N/A72N/A3/31/201941355N/A138N/A12/31/201842857N/A171N/A9/30/201844553N/A178N/A6/30/201843843N/A164N/A3/31/201844128N/A107N/A12/31/201742816N/A51N/A9/30/201742116N/A22N/A6/30/20174037N/A40N/A3/31/2017366-5N/A47N/A12/31/2016336-12N/A35N/A9/30/2016297-44N/A18N/A6/30/2016276-49N/A-45N/A3/31/2016269-61N/A-62N/A12/31/2015261-63N/A-110N/A9/30/2015251-53N/A-114N/A6/30/2015247-48N/A-91N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1783の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 1783の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 1783の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 1783の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 1783の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1783の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/25 11:33終値2026/06/25 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Maxigen Biotech Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Regina LeeCapital Securities CorporationHsiu Chi LinMasterlink Securities Investment Advisory
Reported Earnings • May 01First quarter 2026 earnings released: EPS: NT$0.59 (vs NT$0.53 in 1Q 2025)First quarter 2026 results: EPS: NT$0.59 (up from NT$0.53 in 1Q 2025). Revenue: NT$190.9m (up 7.7% from 1Q 2025). Net income: NT$52.8m (up 12% from 1Q 2025). Profit margin: 28% (up from 27% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$2.96 (vs NT$2.13 in FY 2024)Full year 2025 results: EPS: NT$2.96 (up from NT$2.13 in FY 2024). Revenue: NT$811.6m (up 19% from FY 2024). Net income: NT$265.3m (up 40% from FY 2024). Profit margin: 33% (up from 28% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • Mar 12Maxigen Biotech Inc., Annual General Meeting, Jun 11, 2026Maxigen Biotech Inc., Annual General Meeting, Jun 11, 2026. Location: 3 floor no,88, k`o chi 1st rd., gueishan district, taoyuan city Taiwan
Reported Earnings • Nov 12Third quarter 2025 earnings released: EPS: NT$0.84 (vs NT$0.56 in 3Q 2024)Third quarter 2025 results: EPS: NT$0.84 (up from NT$0.56 in 3Q 2024). Revenue: NT$200.9m (up 16% from 3Q 2024). Net income: NT$75.5m (up 53% from 3Q 2024). Profit margin: 38% (up from 28% in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Aug 29Upcoming dividend of NT$0.83 per shareEligible shareholders must have bought the stock before 05 September 2025. Payment date: 30 September 2025. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Taiwanese dividend payers (5.3%). Higher than average of industry peers (1.1%).
Reported Earnings • Aug 13Second quarter 2025 earnings released: EPS: NT$0.66 (vs NT$0.67 in 2Q 2024)Second quarter 2025 results: EPS: NT$0.66 (down from NT$0.67 in 2Q 2024). Revenue: NT$208.8m (up 20% from 2Q 2024). Net income: NT$58.9m (down 1.3% from 2Q 2024). Profit margin: 28% (down from 34% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth.
お知らせ • Jun 12Maxigen Biotech Inc. Appoints Shih-An Chen as Independent Director, Effective June 11, 2025Maxigen Biotech Inc. announced the appointment of Shih-An Chen as Independent Director. Shih-An Chen is an Honorary Director of Taichung Veterans General Hospital. The change is due to a by-election, and the effective date of the new appointment is June 11, 2025. Original term from June 13, 2024 to June 12, 2027.
Reported Earnings • May 01First quarter 2025 earnings released: EPS: NT$0.53 (vs NT$0.32 in 1Q 2024)First quarter 2025 results: EPS: NT$0.53 (up from NT$0.32 in 1Q 2024). Revenue: NT$177.2m (up 39% from 1Q 2024). Net income: NT$47.1m (up 66% from 1Q 2024). Profit margin: 27% (up from 22% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 22Maxigen Biotech Inc. to Report Q1, 2025 Results on Apr 29, 2025Maxigen Biotech Inc. announced that they will report Q1, 2025 results on Apr 29, 2025
New Risk • Apr 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.22b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$36.15, the stock trades at a trailing P/E ratio of 16.9x. Average trailing P/E is 28x in the Biotechs industry in Taiwan. Total returns to shareholders of 2.0% over the past three years.
Reported Earnings • Mar 05Full year 2024 earnings released: EPS: NT$2.13 (vs NT$1.87 in FY 2023)Full year 2024 results: EPS: NT$2.13 (up from NT$1.87 in FY 2023). Revenue: NT$680.7m (up 9.4% from FY 2023). Net income: NT$190.2m (up 15% from FY 2023). Profit margin: 28% (up from 27% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth.
お知らせ • Feb 27Maxigen Biotech Inc., Annual General Meeting, Jun 11, 2025Maxigen Biotech Inc., Annual General Meeting, Jun 11, 2025. Location: 3 floor no,88, k`o chi 1st rd., gueishan district, taoyuan city Taiwan
お知らせ • Feb 19Maxigen Biotech Inc. to Report Fiscal Year 2024 Results on Feb 26, 2025Maxigen Biotech Inc. announced that they will report fiscal year 2024 results on Feb 26, 2025
分析記事 • Nov 20Maxigen Biotech's (TWSE:1783) Shareholders Have More To Worry About Than Only Soft EarningsMaxigen Biotech Inc.'s ( TWSE:1783 ) recent weak earnings report didn't cause a big stock movement. We think that...
Reported Earnings • Nov 18Third quarter 2024 earnings released: EPS: NT$0.56 (vs NT$0.47 in 3Q 2023)Third quarter 2024 results: EPS: NT$0.56 (up from NT$0.47 in 3Q 2023). Revenue: NT$173.9m (up 9.1% from 3Q 2023). Net income: NT$49.5m (up 20% from 3Q 2023). Profit margin: 28% (up from 26% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 02Second quarter 2024 earnings released: EPS: NT$0.66 (vs NT$0.70 in 2Q 2023)Second quarter 2024 results: EPS: NT$0.66 (down from NT$0.70 in 2Q 2023). Revenue: NT$174.0m (up 1.8% from 2Q 2023). Net income: NT$59.7m (down 4.2% from 2Q 2023). Profit margin: 34% (down from 37% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
お知らせ • Jul 20Maxigen Biotech Inc. to Report Q2, 2024 Results on Jul 29, 2024Maxigen Biotech Inc. announced that they will report Q2, 2024 results on Jul 29, 2024
Upcoming Dividend • Jul 16Upcoming dividend of NT$1.00 per shareEligible shareholders must have bought the stock before 23 July 2024. Payment date: 16 August 2024. Payout ratio is a comfortable 59% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of Taiwanese dividend payers (4.2%). Lower than average of industry peers (2.5%).
New Risk • May 24New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
Reported Earnings • May 07First quarter 2024 earnings released: EPS: NT$0.32 (vs NT$0.50 in 1Q 2023)First quarter 2024 results: EPS: NT$0.32 (down from NT$0.50 in 1Q 2023). Revenue: NT$127.1m (down 11% from 1Q 2023). Net income: NT$28.4m (down 36% from 1Q 2023). Profit margin: 22% (down from 31% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 28Maxigen Biotech Inc. to Report Q1, 2024 Results on May 03, 2024Maxigen Biotech Inc. announced that they will report Q1, 2024 results at 9:00 AM, Taipei Standard Time on May 03, 2024
分析記事 • Mar 28Maxigen Biotech's (TWSE:1783) Earnings Are Of Questionable QualityDespite posting some strong earnings, the market for Maxigen Biotech Inc.'s ( TWSE:1783 ) stock hasn't moved much. We...
Reported Earnings • Mar 24Full year 2023 earnings released: EPS: NT$1.86 (vs NT$1.57 in FY 2022)Full year 2023 results: EPS: NT$1.86 (up from NT$1.57 in FY 2022). Revenue: NT$622.1m (up 2.9% from FY 2022). Net income: NT$165.8m (up 19% from FY 2022). Profit margin: 27% (up from 23% in FY 2022). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 14Maxigen Biotech Inc., Annual General Meeting, Jun 13, 2024Maxigen Biotech Inc., Annual General Meeting, Jun 13, 2024. Location: location:No. 88, Keji 1st Rd., Guishan District Taoyuan City 3rd Floor Meeting Room of the Company Taoyuan Taiwan Agenda: To consider the Company's 2023 Business Report; to audit Committee's review of the 2023 annual final accounting books and statements; to consider 2023 Annual Report on remuneration of Individual Directors; and to discuss other matters.
Buying Opportunity • Oct 12Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be NT$64.46, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 36%.
Upcoming Dividend • Aug 31Upcoming dividend of NT$0.50 per share at 0.9% yieldEligible shareholders must have bought the stock before 07 September 2023. Payment date: 12 October 2023. Trailing yield: 0.9%. Lower than top quartile of Taiwanese dividend payers (5.6%). Lower than average of industry peers (3.0%).
お知らせ • Aug 24Maxigen Biotech Inc. Declares Dividend, Payable on October 12, 2023Maxigen Biotech Inc. announced cash dividends of TWD 42,349,579 with TWD 0.5 distribution per share. Ex-rights (ex-dividend) trading date is September 7, 2023. Ex-rights (ex-dividend) record date is September 13, 2023. Payment date of cash dividend distribution is October 12, 2023.
Buying Opportunity • Aug 23Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 8.9%. The fair value is estimated to be NT$68.33, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 36%.
Reported Earnings • Jul 27Second quarter 2023 earnings released: EPS: NT$0.74 (vs NT$0.40 in 2Q 2022)Second quarter 2023 results: EPS: NT$0.74 (up from NT$0.40 in 2Q 2022). Revenue: NT$170.9m (up 11% from 2Q 2022). Net income: NT$62.3m (up 86% from 2Q 2022). Profit margin: 37% (up from 22% in 2Q 2022). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 36% per year whereas the company’s share price has increased by 40% per year.
Buying Opportunity • Jun 28Now 21% undervaluedOver the last 90 days, the stock is up 12%. The fair value is estimated to be NT$78.69, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 29%.
お知らせ • May 05Maxigen Biotech Inc. Announces Cash Dividend for the Period from January 1, 2022 to December 31, 2022Maxigen Biotech Inc. announced cash dividend of TWD 0.5 per share to the shareholders for the period from January 1, 2022 to December 31, 2022.
Valuation Update With 7 Day Price Move • May 04Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$69.30, the stock trades at a trailing P/E ratio of 42.1x. Average trailing P/E is 34x in the Personal Products industry in Taiwan. Total returns to shareholders of 189% over the past three years.
Reported Earnings • Mar 26Full year 2022 earnings released: EPS: NT$1.65 (vs NT$1.10 in FY 2021)Full year 2022 results: EPS: NT$1.65 (up from NT$1.10 in FY 2021). Revenue: NT$604.4m (up 18% from FY 2021). Net income: NT$139.4m (up 59% from FY 2021). Profit margin: 23% (up from 17% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 58% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 16%After last week's 16% share price gain to NT$57.80, the stock trades at a trailing P/E ratio of 44.5x. Average trailing P/E is 30x in the Personal Products industry in Taiwan. Total returns to shareholders of 183% over the past three years.
お知らせ • Dec 30Maxigen Biotech Inc. Announces Resignation of You Wan-How as Financial Officer and Accounting OfficerMaxigen Biotech Inc. Announces Resignation of You Wan-How as Financial Officer and Accounting Officer. Type of personnel changed: financial officer and accounting officer. Date of occurrence of the change:2022/12/29. Name, title, and resume of the previous position holder: You Wan-How/financial officer and accounting officer of MBI. Name, title, and resume of the new position holder: None. Type of the change: Resignation. Effective date:2022/12/29. The new financial and accounting officer will be announced after audit committee and the board of directors approve the appointment.
Board Change • Nov 16Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 3 independent directors (4 non-independent directors). Representative Director Tsiu-Yuan Li is the most experienced director on the board, commencing their role in 2015. Independent Director Sung-Yuan Liao was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 26Third quarter 2022 earnings released: EPS: NT$0.55 (vs NT$0.42 in 3Q 2021)Third quarter 2022 results: EPS: NT$0.55 (up from NT$0.42 in 3Q 2021). Revenue: NT$162.6m (up 17% from 3Q 2021). Net income: NT$42.1m (up 36% from 3Q 2021). Profit margin: 26% (up from 22% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 06Second quarter 2022 earnings released: EPS: NT$0.43 (vs NT$0.31 in 2Q 2021)Second quarter 2022 results: EPS: NT$0.43 (up from NT$0.31 in 2Q 2021). Revenue: NT$154.2m (up 27% from 2Q 2021). Net income: NT$33.5m (up 56% from 2Q 2021). Profit margin: 22% (up from 18% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 19% per year.
Valuation Update With 7 Day Price Move • Jun 30Investor sentiment improved over the past weekAfter last week's 17% share price gain to NT$48.00, the stock trades at a trailing P/E ratio of 42.7x. Average trailing P/E is 18x in the Personal Products industry in Taiwan. Total returns to shareholders of 96% over the past three years.
お知らせ • May 14Maxigen Biotech Inc. Announces Resignation of Lu Min Hsuan as Chief Internal AuditorMaxigen Biotech Inc. announced the resignation of Lu Min Hsuan as chief internal auditor of the company, with effect from May 13, 2022. The new chief internal auditor will be announced after audit committee and the board of directors approve the appointment.
Reported Earnings • May 04First quarter 2022 earnings released: EPS: NT$0.27 (vs NT$0.31 in 1Q 2021)First quarter 2022 results: EPS: NT$0.27 (down from NT$0.31 in 1Q 2021). Revenue: NT$123.3m (up 11% from 1Q 2021). Net income: NT$20.5m (down 5.0% from 1Q 2021). Profit margin: 17% (down from 20% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 15% per year.
お知らせ • May 04+ 1 more updateMaxigen Biotech Inc. Appoints Lin Yung-Hsiang to Nomination CommitteeMaxigen Biotech Inc. announced the appointment of Lin Yung-Hsiang to the Company's Nomination Committee, with effect from May 3, 2022.
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to NT$37.65, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 56% over the past three years.
Board Change • Apr 27Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Zhong Ming Zeng is the most experienced director on the board, commencing their role in 2021. Independent Director Song-Yuan Liao was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Mar 23Maxigen Biotech Inc., Annual General Meeting, Jun 21, 2022Maxigen Biotech Inc., Annual General Meeting, Jun 21, 2022. Location: No. 88, Keji 1st Rd., Guishan District (3rd Floor Meeting Room of the Company) Taoyuan City Taiwan Agenda: To consider the Company's 2021 Business Report; to consider audit committee's review of the 2021 annual final accounting books and statements; to consider report on 2021 employees and Directors' remuneration; to consider 2021 Annual Report on remuneration of Individual Directors; to consider 2021 Business Report and Financial Statements; to consider proposal of 2021 earnings distribution; to consider issue new shares through the capitalization of retained earnings; to approve the lifting of non competition restrictions for directors and representatives; and to consider and discuss other matters (if any).
Reported Earnings • Nov 12Third quarter 2021 earnings released: EPS NT$0.42 (vs NT$0.18 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: NT$138.6m (up 20% from 3Q 2020). Net income: NT$30.9m (up 153% from 3Q 2020). Profit margin: 22% (up from 11% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 43% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Oct 04Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to NT$51.80, the stock trades at a trailing P/E ratio of 52.8x. Average trailing P/E is 14x in the Personal Products industry in Taiwan. Total returns to shareholders of 99% over the past three years.
Reported Earnings • Aug 12Second quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.30 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: NT$121.1m (up 4.0% from 2Q 2020). Net income: NT$21.4m (up 4.2% from 2Q 2020). Profit margin: 18% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Aug 12Upcoming dividend of NT$0.73 per shareEligible shareholders must have bought the stock before 19 August 2021. Payment date: 13 September 2021. Trailing yield: 1.1%. Lower than top quartile of Taiwanese dividend payers (5.1%). Lower than average of industry peers (3.7%).
Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improved over the past weekAfter last week's 24% share price gain to NT$49.65, the stock trades at a trailing P/E ratio of 46.1x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total returns to shareholders of 72% over the past three years.
Reported Earnings • May 16First quarter 2021 earnings released: EPS NT$0.31 (vs NT$0.15 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: NT$111.0m (up 7.4% from 1Q 2020). Net income: NT$21.6m (up 112% from 1Q 2020). Profit margin: 20% (up from 9.9% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
分析記事 • Apr 22Maxigen Biotech Inc. (TPE:1783) Is Yielding 2.3% - But Is It A Buy?Could Maxigen Biotech Inc. ( TPE:1783 ) be an attractive dividend share to own for the long haul? Investors are often...
分析記事 • Apr 01We Think You Should Be Aware Of Some Concerning Factors In Maxigen Biotech's (TPE:1783) EarningsThe market shrugged off Maxigen Biotech Inc.'s ( TPE:1783 ) solid earnings report. We think that investors might be...
Reported Earnings • Mar 23Full year 2020 earnings released: EPS NT$0.91 (vs NT$0.86 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: NT$457.7m (up 1.2% from FY 2019). Net income: NT$63.3m (up 5.3% from FY 2019). Profit margin: 14% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth.
分析記事 • Mar 16Maxigen Biotech Inc.'s (TPE:1783) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?Maxigen Biotech's (TPE:1783) stock is up by a considerable 26% over the past three months. Given that stock prices are...
Valuation Update With 7 Day Price Move • Mar 09Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$27.50, the stock is trading at a trailing P/E ratio of 37.9x, up from the previous P/E ratio of 32.3x. This compares to an average P/E of 17x in the Personal Products industry in Taiwan. Total returns to shareholders over the past three years are 36%.
分析記事 • Feb 23The Maxigen Biotech (TPE:1783) Share Price Has Gained 22% And Shareholders Are Hoping For MoreBuying a low-cost index fund will get you the average market return. But if you invest in individual stocks, some are...
Is New 90 Day High Low • Feb 20New 90-day high: NT$24.00The company is up 2.0% from its price of NT$23.50 on 20 November 2020. The Taiwanese market is up 19% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Personal Products industry, which is down 6.0% over the same period.
分析記事 • Feb 02Can Maxigen Biotech (TPE:1783) Continue To Grow Its Returns On Capital?Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...
分析記事 • Jan 10Tread With Caution Around Maxigen Biotech Inc.'s (TPE:1783) 3.4% Dividend YieldToday we'll take a closer look at Maxigen Biotech Inc. ( TPE:1783 ) from a dividend investor's perspective. Owning a...
分析記事 • Dec 14Declining Stock and Decent Financials: Is The Market Wrong About Maxigen Biotech Inc. (TPE:1783)?Maxigen Biotech (TPE:1783) has had a rough three months with its share price down 7.2%. However, the company's...
分析記事 • Nov 22If You Had Bought Maxigen Biotech's (TPE:1783) Shares Five Years Ago You Would Be Down 13%Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results...
Reported Earnings • Nov 15Third quarter 2020 earnings released: EPS NT$0.18The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2020 results: Revenue: NT$115.1m (down 4.6% from 3Q 2019). Net income: NT$12.2m (down 37% from 3Q 2019). Profit margin: 11% (down from 16% in 3Q 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 30New 90-day low: NT$22.15The company is down 19% from its price of NT$27.25 on 31 July 2020. The Taiwanese market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is down 9.0% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: NT$23.05The company is down 21% from its price of NT$29.35 on 24 June 2020. The Taiwanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 2.0% over the same period.